<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010036.anc" start="33520" end="33525" sStart="33470" offset="50" sid="r7.1.use.v.0330" wn="1" wnkey="use%2:34:01::" text="Some promising results have been obtained using immunomodulatory drugs, including cyclosporine [60] and hydroxyurea [61], in combination with antiviral therapy, presumably because of the limitation of T cell activation." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010036.anc" start="25792" end="25802" sStart="null" offset="33" sid="r1.successful.j.0088" wn="1" wnkey="successful%3:00:00::" text="Moreover, even during periods of successful control of viremia, progressive loss of CD4+ T cells was frequently observed." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010036.anc" start="25792" end="25802" sStart="null" offset="33" sid="r1.successful.j.0088" wn="1" wnkey="successful%3:00:00::" text="Moreover, even during periods of successful control of viremia, progressive loss of CD4+ T cells was frequently observed." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010036.anc" start="25792" end="25802" sStart="null" offset="33" sid="r1.successful.j.0088" wn="1" wnkey="successful%3:00:00::" text="Moreover, even during periods of successful control of viremia, progressive loss of CD4+ T cells was frequently observed." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010036.anc" start="29171" end="29177" sStart="null" offset="74" sid="r11.strong.j.0779" wn="2" wnkey="strong%5:00:00:intense:00" text="In one individual (AC-06), HIV-1 superinfection in the setting of strong and broadly directed HIV-specific cellular immune responses was associated with the loss of viral control, as previously reported [29]." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010036.anc" start="34567" end="34578" sStart="null" offset="235" sid="r11.recommend.v.0774" wn="1" wnkey="recommend%2:32:01::" text="The definition of failure chosen for this study was a viral load of greater than 5,000 RNA copies/ml plasma, which at the time the study was initiated corresponded to the level of viremia at which treatment was recommended." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0010036.anc" start="28369" end="28374" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" text="Mechanisms leading to &lt;b&gt;rapid&lt;/b&gt; CD4+ T cell loss need to be further studied in future STI trials." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0010036.anc" start="28369" end="28374" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" text="Mechanisms leading to &lt;b&gt;rapid&lt;/b&gt; CD4+ T cell loss need to be further studied in future STI trials." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0010036.anc" start="28369" end="28374" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" text="Mechanisms leading to &lt;b&gt;rapid&lt;/b&gt; CD4+ T cell loss need to be further studied in future STI trials." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0010036.anc" start="28369" end="28374" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" text="Mechanisms leading to &lt;b&gt;rapid&lt;/b&gt; CD4+ T cell loss need to be further studied in future STI trials." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0010036.anc" start="28369" end="28374" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" text="Mechanisms leading to &lt;b&gt;rapid&lt;/b&gt; CD4+ T cell loss need to be further studied in future STI trials." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0010036.anc" start="28369" end="28374" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" text="Mechanisms leading to &lt;b&gt;rapid&lt;/b&gt; CD4+ T cell loss need to be further studied in future STI trials." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0010036.anc" start="34904" end="34909" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" text="In studies of untreated infection, there is only a 5-fold difference in viremia separating the quartile with the slowest disease progression from the quartile with the most &lt;b&gt;rapid&lt;/b&gt; progression [63], suggesting that small differences in steady-state viremia may influence clinical outcome." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0010036.anc" start="28369" end="28374" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" text="Mechanisms leading to &lt;b&gt;rapid&lt;/b&gt; CD4+ T cell loss need to be further studied in future STI trials." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0010036.anc" start="28369" end="28374" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" text="Mechanisms leading to &lt;b&gt;rapid&lt;/b&gt; CD4+ T cell loss need to be further studied in future STI trials." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/plos/pmed.0010036.anc" start="28369" end="28374" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" text="Mechanisms leading to &lt;b&gt;rapid&lt;/b&gt; CD4+ T cell loss need to be further studied in future STI trials." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010036.anc" start="29966" end="29976" sStart="null" offset="3" sid="r10.particular.j.0610" wn="3" wnkey="particular%5:00:00:uncommon:00" text="In particular, even a low level of viremia correlates with a low or undetectable frequency of interleukin-2-producing HIV-1-specific memory CD4+ T cells endowed with proliferative capacity in vitro [36,37,38,39], thus abrogating CD4+ T cell help crucial to maintain efficacy of CD8+ T cell functions." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010036.anc" start="31956" end="31962" sStart="null" offset="128" sid="r8.number.n.0439" wn="1" wnkey="number%1:07:00::" text="In chronic HIV-1 infection, STI studies showed only marginal, if any, improvements of HIV-1 viremia control following a number of treatment interruptions cycles, despite at least transient increases in HIV-1-specific CD8+ and CD4+ T cell responses [4,5,52,53,54,55]." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010036.anc" start="31543" end="31552" sStart="null" offset="54" sid="r11.function.n.0120" wn="2" wnkey="function%1:07:00::" text="Assessing the changes in CD4+ and CD8+ T cell functions over time as well as viral evolution under immune selection pressure will be important to evaluate immune correlates in this cohort." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010036.anc" start="18913" end="18917" sStart="null" offset="217" sid="r9.fold.v.0395" wn="2147483645" wnkey="null" text="The only parameter that was predictive of prolonged viral control during the first treatment interruption was a low viremia at time of institution of therapy ( p = 0.01): there was a 2.8-fold increase in hazard per order of magnitude increase in viral load." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010036.anc" start="34776" end="34780" sStart="null" offset="61" sid="r9.fold.v.0392" wn="2147483645" wnkey="null" text="In studies of untreated infection, there is only a 5-fold difference in viremia separating the quartile with the slowest disease progression from the quartile with the most rapid progression [63], suggesting that small differences in steady-state viremia may influence clinical outcome." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010036.anc" start="19304" end="19311" sStart="null" offset="62" sid="r10.control.n.0809" wn="2" wnkey="control%1:24:00::" text="Although 11 out of 14 individuals achieved at least transient control of viremia, and three experienced prolonged control, none of these patients possessed the HLA alleles B27 or B57 associated with better disease outcome [24,25]." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010036.anc" start="13153" end="13160" sStart="null" offset="20" sid="r10.control.n.0729" wn="2" wnkey="control%1:24:00::" text="Duration of viremia control during successive treatment interruptions was highly variable, and there was no increase in the sustainability of viral containment during successive STI cycles." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010036.anc" start="27005" end="27012" sStart="null" offset="173" sid="r10.control.n.0665" wn="1" wnkey="control%1:07:00::" text="Clinical, genetic, and immunological parameters did not distinguish these three individuals from the other 11 patients, nor did they predict the duration of control following treatment interruption." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010036.anc" start="25051" end="25058" sStart="null" offset="106" sid="r10.control.n.0652" wn="3" wnkey="control%1:04:02::" text="Although early treatment of acute HIV-1 infection followed by treatment interruptions may enhance control of viremia [6,8], the durability of this control remains unclear." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010036.anc" start="14381" end="14388" sStart="null" offset="87" sid="r10.control.n.0538" wn="2" wnkey="control%1:24:00::" text="Moreover, the data do not show a consistent pattern of augmentation of viral control with sequential treatment interruptions." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010036.anc" start="29890" end="29897" sStart="null" offset="223" sid="r10.control.n.0322" wn="4" wnkey="control%1:09:02::" text="Numerous studies now indicate that IFN-? production alone is not associated with viral load [19,30,31] but rather that functional characteristics of CD4+ and CD8+ T cells may be better associated with viral control [32,33,34,35]." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010036.anc" start="4527" end="4533" sStart="null" offset="148" sid="r10.board.n.0126" wn="1" wnkey="board%1:14:00::" text="All individuals gave written informed consent to participate, and the study was approved by the respective institutional review boards and conducted in accordance with the human experimentation guidelines of the Massachusetts General Hospital." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010036.anc" start="32317" end="32325" sStart="null" offset="84" sid="r11.benefit.n.0789" wn="2" wnkey="benefit%1:07:00::" text="Other studies of STI after treated acute HIV-1 infection have shown limited benefits [9], including recent trials such as the PrimSTOP trial [57] and the QUEST study [58]." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010036.anc" start="18578" end="18585" sStart="null" offset="376" sid="r11.absence.n.0475" wn="1" wnkey="absence%1:26:00::" text="The individuals who controlled viremia for a longer time either during the first STI or during any of the treatment interruptions were not different from those who experienced earlier breakthrough as measured by ELISA and Western blot status at initiation of HAART, coreceptor polymorphisms (CCR5delta32, CCR2 V64I), or the presence or absence of GBV-C coinfection (Cox proportional hazards model, p &gt;0." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010036.anc" start="17913" end="17920" sStart="null" offset="217" sid="r11.absence.n.0262" wn="1" wnkey="absence%1:26:00::" text="Analyses included clinical and laboratory parameters at time of presentation with acute HIV-1 infection, genetic markers associated with different rates of disease progression, and the presence or absence of GBV-C coinfection." />
  </sentences>
</list>